Sign In
Buy ICCM
$0.152
+0.0127 (+9.14%)
At Close: Jun 03, 2026
IceCure Reports Preliminary Financial Results for the Three and Six Months Ended June 30, 2025
08:30am, Thursday, 03'rd Jul 2025
CAESAREA, Israel , July 3, 2025 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destr
IceCure Announces Record Date for Rights Offering for Up to $10 Million
09:23am, Wednesday, 25'th Jun 2025
CAESAREA, Israel , June 25, 2025 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destr
IceCure Receives Notice of Patent Allowance in U.S. for a Novel Cryogen Flow Control to Optimize Patient Outcomes
08:30am, Monday, 09'th Jun 2025
IceCure has 20+ patents in the U.S. and the Company anticipates further market traction upon FDA's marketing authorization decision in early-stage breast cancer CAESAREA, Israel , June 9, 2025 /PRNews
IceCure Medical Ltd (ICCM) Q1 2025 Earnings Call Transcript
04:26pm, Wednesday, 28'th May 2025
IceCure Medical Ltd (NASDAQ:ICCM ) Q1 2025 Earnings Conference Call May 28, 2025 10:00 AM ET Company Participants Michael Polyviou - IR Eyal Shamir - CEO Ronen Tsimerman - CFO and COO Conference Call
IceCure Medical Reports First Quarter 2025 Financial Results
08:30am, Wednesday, 28'th May 2025
Recently finalized and delivered proposed post market study plan to the FDA; Awaiting marketing authorization decision for ProSense® in women aged 70+ with early-stage low risk breast cancer Continue
IceCure to Report First Quarter 2025 Financial & Operational Results on May 28, 2025
08:30am, Wednesday, 21'st May 2025
CAESAREA, Israel , May 21, 2025 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destr
Breast surgeons expressed strong interest in participating in IceCure's planned post-market study for ProSense® in the treatment of early-stage breast cancer ICE3 study named as one of the "Best Pap
Final marketing authorization decision for early-stage breast cancer is expected upon the FDA's approval of IceCure's post-market study plan IceCure to engage with potential clinical sites, breast su
IceCure Exhibits ProSense® & Sponsors Breast Cryoablation Courses at the Society of Breast Imaging Symposium
08:30am, Monday, 28'th Apr 2025
Two sold-out SBI breast cryoablation courses featured hands-on training with ProSense® IceCure hosted a VIP Exhibitor Hour featuring Dr. Robert C. Ward, a specialist in women's imaging and breast cry
IceCure's ProSense® Featured at European Conference on Interventional Oncology with an Emphasis on Breast Cancer Cryoablation
08:30am, Tuesday, 22'nd Apr 2025
Breast cancer cryoablation was a major focus at ECIO 2025 with a dedicated scientific session Independent studies of ProSense® featured in scientific sessions and abstracts including data from the TH
IceCure Medical Stock Dips Despite Positive ICESECRET Study Results
10:20am, Friday, 28'th Mar 2025
ICCM reports strong kidney cancer cryoablation study results, showcasing 88.7% recurrence-free rates and reinforcing its position in cryoablation technology.
IceCure Medical Ltd (ICCM) Q4 2024 Earnings Call Transcript
01:45pm, Thursday, 27'th Mar 2025
IceCure Medical Ltd (NASDAQ:ICCM ) Q4 2024 Earnings Conference Call March 27, 2025 10:00 AM ET Company Participants Michael Polyviou - Investor Relations Eyal Shamir - Chief Executive Officer and Dire
IceCure Medical Reports 2024 Financial Results: 42% Growth in ProSense® Cryoablation Sales in North America
08:30am, Thursday, 27'th Mar 2025
Expecting FDA decision on marketing authorization for early-stage low risk breast cancer with endocrine therapy Positive ProSense® results were reported through 33 peer-reviewed journals and medical
Interim Data confirm ProSense® cryoablation is highly effective for kidney tumors ≤3 cm and a safe procedure for kidney tumors ≤5 cm in people ineligible for surgery CAESAREA, Israel , March
IceCure Medical to Report 2024 Full Year Financial & Operational Results on March 27, 2025
08:30am, Friday, 21'st Mar 2025
CAESAREA, Israel , March 21, 2025 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that des
